Insights
EQ-5D and beyond: OHE’s contributions to EuroQol research and meetings
27 February 2025
Measuring and valuing health outcomes is arguably what makes health economics such a unique and sometimes controversial discipline. The idea of putting a numerical value on…
Driving Green Change: Lessons from the 2024 Innovation Policy Prize
5 February 2025
Last week, the OHE Innovation Policy Prize was jointly awarded to Professor Andrew Briggs and Professor Thomas Pogge.
Infectious disease: another reason to try Veganuary for the NHS
30 January 2025
We dust off last year’s model to consider the potential savings to the NHS from more people going vegan, with a focus on COVID-19.
OHE’s submission for the DHSC’s next 10 years of planning
9 December 2024
This Insight summarises the recommendations OHE submitted towards the Department of Health & Social Care’s consultation on the next 10 years of planning for the NHS.
Latest estimates show that 20 people a day die in unrelieved pain across the UK at the end of their lives
26 November 2024
To help inform the current debate on assisted dying, we have updated the findings of our 2019 palliative report with the latest data.
What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
19 November 2024
A critique of the recent EEPRU paper
Is collaboration between and across regulatory and HTA agencies the answer to access challenges?
12 November 2024
More collaborative initiatives are taking place among regulatory agencies, health technology assessment (HTA) bodies and between regulatory and HTA agencies at national and regional levels.
The Preventive Health Revolution: Insights from the 2024 Annual Lecture
15 October 2024
One of OHE’s charitable objectives is a commitment to educate and inform the public and policymakers about critical issues in the healthcare sector. OHE’s Annual Lecture…
Drug shortages are on the rise – but what is their impact?
16 September 2024
In this article, we discuss the global issue of drug shortages. We summarise our research where we developed a framework for quantifying the cost of a shortage, and through three case studies provide illustrative estimates of these costs.